Alzinova (78D) Stock Overview
A clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
78D Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Alzinova AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.08 |
| 52 Week High | SEK 0.25 |
| 52 Week Low | SEK 0.0067 |
| Beta | 1.11 |
| 1 Month Change | 168.12% |
| 3 Month Change | 768.48% |
| 1 Year Change | -28.66% |
| 3 Year Change | -70.79% |
| 5 Year Change | -89.07% |
| Change since IPO | -87.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78D | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -1.3% | 1.9% |
| 1Y | -28.7% | 7.8% | 4.1% |
Return vs Industry: 78D underperformed the German Biotechs industry which returned 7.1% over the past year.
Return vs Market: 78D underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| 78D volatility | |
|---|---|
| 78D Average Weekly Movement | 230.4% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 78D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 78D's weekly volatility has increased from 134% to 230% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 7 | Tord Labuda | www.alzinova.com |
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. The company’s lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study.
Alzinova AB (publ) Fundamentals Summary
| 78D fundamental statistics | |
|---|---|
| Market cap | €19.00m |
| Earnings (TTM) | -€2.42m |
| Revenue (TTM) | €2.34m |
Is 78D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78D income statement (TTM) | |
|---|---|
| Revenue | SEK 25.66m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 25.66m |
| Other Expenses | SEK 52.23m |
| Earnings | -SEK 26.57m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -103.58% |
| Debt/Equity Ratio | 0.5% |
How did 78D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/05 07:48 |
| End of Day Share Price | 2026/08/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alzinova AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maria Karlsson Osipova | DNB Carnegie Commissioned Research |
| Ludvig Svensson | DNB Carnegie Commissioned Research |
| Fredrik Thor | Redeye |